# Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

> **NCT05270213** · PHASE1 · RECRUITING · sponsor: **Riboscience, LLC.** · enrollment: 164 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** RBS2418
- **DRUG:** Pembrolizumab
- **DRUG:** Other approved anti-cancer therapy

## Key facts

- **NCT ID:** NCT05270213
- **Lead sponsor:** Riboscience, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-11
- **Primary completion:** 2027-04
- **Final completion:** 2027-12
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05270213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05270213, "Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05270213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*